Phio Pharmaceuticals Corp (PHIO) Stock Price, Quote & News

Company Profile

Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma a...

Industry: Biotechnology

Sector: Healthcare

Phone: 508 767 3861

Website: phiopharma.com

Address:

11 Apex Drive, Suite 300A PMB 2006, Marlborough, United States

DosGatos Dec. 31 at 2:21 AM

$PHIO

1 · Reply

DosGatos Dec. 30 at 11:14 PM

$PHIO joke of an insider buy - 5k?!!!!! Pumpers gonna love it!!

1 · Reply

RetiredOldGeezer Dec. 30 at 3:36 AM

$PHIO Question for the experts - if CEO buys stock - does that mean no news is likely for at least 30 days? Would a major announcement be considered insider trading? Trying to decide if CEO buy is short term negative.

0 · Reply

trader_23 Dec. 29 at 8:37 PM

$PHIO BULLISH! I found this article for you: - https://za.investing.com/news/insider-trading-news/phio-pharmaceuticals-chairman-bitterman-buys-5100-in-stock-93CH-4041733

1 · Reply

ForeverTrades Dec. 29 at 6:00 PM

🚨 $PHIO UPDATE 🚨 Some CEO adds today $1.02

0 · Reply

CEOBuysDisclosures Dec. 29 at 3:15 PM

$PHIO CEO purchased 5,000 shares at $1.02 for a total of $5,100. Bitterman Robert J now owns 286,421 shares. https://ceo-buys.com

0 · Reply

trader_23 Dec. 29 at 2:23 AM

$PHIO Still bullish. Our time is coming

1 · Reply

mjross999 Dec. 26 at 4:23 PM

$PHIO Trial now active, you can track here https://clinicaltrials.gov/study/NCT06014086

0 · Reply

PitaPierogi Dec. 26 at 2:50 PM

$PHIO

0 · Reply

jarias115 Dec. 26 at 2:46 PM

$PHIO I think come February, will be over 1.5

0 · Reply

Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762

Nov 25, 2025, 11:30 AM EST - 5 weeks ago

Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762

Nov 17, 2025, 8:45 AM EST - 6 weeks ago

Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

Nov 13, 2025, 4:15 PM EST - 6 weeks ago

Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 7, 2025, 10:30 AM EST - 7 weeks ago

Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

Nov 7, 2025, 7:45 AM EST - 7 weeks ago

Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

Nov 3, 2025, 1:40 PM EST - 2 months ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

Nov 3, 2025, 7:45 AM EST - 2 months ago

Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

Oct 31, 2025, 10:15 AM EDT - 2 months ago

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

Oct 21, 2025, 7:45 AM EDT - 2 months ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Sep 18, 2025, 7:45 AM EDT - 3 months ago

Phio Pharmaceuticals to Present at the Life Sciences Future Conference

Sep 3, 2025, 7:45 AM EDT - 4 months ago

Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 4:15 PM EDT - 4 months ago

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 25, 2025, 3:04 PM EDT - 5 months ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Jul 25, 2025, 12:36 PM EDT - 5 months ago

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Jul 25, 2025, 7:45 AM EDT - 5 months ago

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Jun 25, 2025, 7:45 AM EDT - 6 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

Jun 24, 2025, 7:45 AM EDT - 6 months ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jun 6, 2025, 7:45 AM EDT - 7 months ago

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio

May 19, 2025, 7:45 AM EDT - 8 months ago

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

May 15, 2025, 4:15 PM EDT - 8 months ago

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 7:45 AM EDT - 8 months ago

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

Apr 9, 2025, 7:45 AM EDT - 9 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Apr 3, 2025, 7:45 AM EDT - 9 months ago

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Mar 31, 2025, 4:00 PM EDT - 9 months ago

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Mar 10, 2025, 7:45 AM EDT - 10 months ago

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Mar 5, 2025, 7:45 AM EST - 10 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Feb 20, 2025, 7:45 AM EST - 11 months ago

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Jan 22, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jan 21, 2025, 4:15 PM EST - 1 year ago

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 16, 2025, 1:00 PM EST - 1 year ago

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 15, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 14, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 13, 2025, 12:45 PM EST - 1 year ago

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

Jan 13, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Jan 2, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Dec 23, 2024, 1:15 PM EST - 1 year ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 2:28 PM EST - 1 year ago

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Dec 12, 2024, 9:21 AM EST - 1 year ago

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Dec 10, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Nov 19, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Nov 14, 2024, 5:47 PM EST - 1 year ago

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 10:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 18, 2024, 1:30 PM EDT - 1 year ago

Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Oct 18, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells

Sep 25, 2024, 8:00 AM EDT - 1 year ago

INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society

Sep 16, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA

DosGatos Dec. 31 at 2:21 AM

$PHIO

1 · Reply

DosGatos Dec. 30 at 11:14 PM

$PHIO joke of an insider buy - 5k?!!!!! Pumpers gonna love it!!

1 · Reply

RetiredOldGeezer Dec. 30 at 3:36 AM

0 · Reply

trader_23 Dec. 29 at 8:37 PM

$PHIO BULLISH! I found this article for you: - https://za.investing.com/news/insider-trading-news/phio-pharmaceuticals-chairman-bitterman-buys-5100-in-stock-93CH-4041733

1 · Reply

ForeverTrades Dec. 29 at 6:00 PM

🚨 $PHIO UPDATE 🚨 Some CEO adds today $1.02

0 · Reply

CEOBuysDisclosures Dec. 29 at 3:15 PM

$PHIO CEO purchased 5,000 shares at $1.02 for a total of $5,100. Bitterman Robert J now owns 286,421 shares. https://ceo-buys.com

0 · Reply

trader_23 Dec. 29 at 2:23 AM

$PHIO Still bullish. Our time is coming

1 · Reply

mjross999 Dec. 26 at 4:23 PM

$PHIO Trial now active, you can track here https://clinicaltrials.gov/study/NCT06014086

0 · Reply

PitaPierogi Dec. 26 at 2:50 PM

$PHIO

0 · Reply

jarias115 Dec. 26 at 2:46 PM

$PHIO I think come February, will be over 1.5

0 · Reply

jarias115 Dec. 24 at 4:03 PM

$PHIO couldn’t fill all my orders 😥😥😥

1 · Reply

ckruel Dec. 24 at 3:29 PM

$PHIO $PHIO Tracked down where that $14 target came from and the analyst commentary, this is what I found….. H.C. Wainwright assumed coverage of Phio Pharmaceuticals with a Buy rating and $14 price target. Phio&#39;s lead asset is PH-762 is an siRNA-based therapy formulated to safely inhibit PD-1 expression on T cells within the tumor microenvironment to drive anti-tumor activity, the analyst tells investors in a research note. The firm believes the company is &quot;flying under the radar with investors&quot; and has a bullish outlook for the stock

0 · Reply

JohnTrack Dec. 24 at 4:06 AM

$PHIO tracking intraday mood...

0 · Reply

RetiredOldGeezer Dec. 24 at 1:22 AM

$PHIO Which will be next - RS or ATM? When a fluffy pump fails there is something about to happen - maybe not good.

0 · Reply

DosGatos Dec. 23 at 10:46 PM

$PHIO Not putting in an order tomorrow at any price

1 · Reply

jarias115 Dec. 23 at 10:40 PM

$PHIO putting in an order tomorrow if under $1

0 · Reply

ForeverTrades Dec. 23 at 9:23 PM

🚨 $PHIO UPDATE 🚨 No movement as of yet, but thats fine, as we are __**25%**__ in and R/R is pretty good. Time is needed

0 · Reply

JohnTrack Dec. 23 at 3:49 PM

$PHIO Announces Significant Step Forward in its Drug Development Program https://www.rapidticker.com/news/phio-phio-pharmaceuticals-announces-significant-step-6ee450

0 · Reply

ckruel Dec. 23 at 3:31 PM

$PHIO The most recent analyst rating on PHIO ▼7.27% stock is a Buy with a $14.00 price target.

0 · Reply

ckruel Dec. 23 at 3:30 PM

$PHIO • Phio secured FDA acceptance of PH-762’s nonclinical study design, enabling a toxicology study. • Positive Phase 1b skin cancer data and manufacturing advances de-risk PH-762’s development path.

0 · Reply

DosGatos Dec. 23 at 3:19 PM

$PHIO one buck ! Merry xmas from geeeeeerrrrrrrrttttttieeee!

0 · Reply

diwhyy Dec. 23 at 2:01 PM

$BBLG watch $PHIO https://nfne.ws/278866 $PHIO @PhioPharma11803 #immunooncology #INTASYL #PH762 #PHIO #siRNA #Chemicals #Pharmaceutical #Biotechnology #Healt

0 · Reply

Market Cap	11.41M
Revenue (ttm)	0.00
Net Income (ttm)	-7.15M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	301,100
Avg Vol	3,685,834
Day's Range	N/A - N/A
Shares Out	10.76M
Stochastic %K	11%
Beta	0.92
Analysts	Sell
Price Target	$14.00